E Naparstek

6.6k total citations · 2 hit papers
65 papers, 5.3k citations indexed

About

E Naparstek is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, E Naparstek has authored 65 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 19 papers in Oncology and 19 papers in Immunology. Recurrent topics in E Naparstek's work include Hematopoietic Stem Cell Transplantation (31 papers), Immune Cell Function and Interaction (9 papers) and Acute Myeloid Leukemia Research (8 papers). E Naparstek is often cited by papers focused on Hematopoietic Stem Cell Transplantation (31 papers), Immune Cell Function and Interaction (9 papers) and Acute Myeloid Leukemia Research (8 papers). E Naparstek collaborates with scholars based in Israel, United States and Italy. E Naparstek's co-authors include Arnon Nagler, Reuven Or, Aliza Ackerstein, Chaim Brautbar, Gabriel Cividalli, Shimon Slavin, Ofira Ben‐Tal, Memet Aker, Simcha Samuel and A Eldor and has published in prestigious journals such as Blood, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

E Naparstek

64 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

1998 1.6k citations Shimon Slavin, Arnon Nagler et al. profile →
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

1998 1.5k citations Shimon Slavin, Arnon Nagler et al. profile →

Peers

Countries citing papers authored by E Naparstek

Since Specialization

Citations

This map shows the geographic impact of E Naparstek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Naparstek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Naparstek more than expected).

Fields of papers citing papers by E Naparstek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E Naparstek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Naparstek. The network helps show where E Naparstek may publish in the future.

Co-authorship network of co-authors of E Naparstek

This figure shows the co-authorship network connecting the top 25 collaborators of E Naparstek. A scholar is included among the top collaborators of E Naparstek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Naparstek. E Naparstek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study 2017 ·Annals of Hematology ·(unknown), Chava Perry, Yair Herishanu, Nadav Sarid, (unknown), Odelia Amit, Rinat Eshel, E Naparstek, Irit Avivi, Ron Ram	0
2	Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study 2017 ·Clinical Microbiology and Infection ·Moshe Yeshurun, Iuliana Vaxman, Liat Shargian, Dafna Yahav, Jihad Bishara, Oren Pasvolsky, Ofir Wolach, Meir Lahav, Ronit Gurion, Hila Magen, Liat Vidal, (unknown), (unknown), Maya Moshe, (unknown), E Naparstek, Pia Raanani, Uri Rozovski	21
3	Leukomogenic factors downregulate heparanase expression in acute myeloid leukemia cells 2005 ·Biochemical and Biophysical Research Communications ·Rinat Eshel, (unknown), (unknown), Yona Nadir, Saverio Minucci, Aaron Polliack, E Naparstek, Israël Vlodavsky, Ben-Zion Katz	6
4	Enoxaparin can be Used Safely in Patients with Severe Thrombocytopenia due to Intensive Chemotherapy Regimens 2004 ·Leukemia & lymphoma ·Yair Herishanu, Mudi Misgav, Ilya Kirgner, Ofira Ben‐Tal, Amiram Eldor, E Naparstek	49
5	Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation 2001 ·Bone Marrow Transplantation ·Rifaat Safadi, Reuven Or, Yaron Ilan, E Naparstek, Arnon Nagler, Andreas Klein, (unknown), Koray Ergünay, D. Danon, Daniel Shouval, Eithan Galun	64
6	The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases 1999 ·Bone Marrow Transplantation ·(unknown), Nili Peylan‐Ramu, Gabriel Cividalli, G. Váradi, R. Or, E Naparstek, S Slavin, Arnon Nagler	14
7	Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease 1999 ·Bone Marrow Transplantation ·Arnon Nagler, Aliza Ackerstein, Joseph Kapelushnik, Reuven Or, E Naparstek, S Slavin	41
8	SELECTIVE CD4+ T-CELL DEPLETION DOES NOT PREVENT GRAFT-VERSUS-HOST DISEASE1 1998 ·Transplantation ·Arnon Nagler, Reba Condiotti, (unknown), E Naparstek, Reuven Or, Simcha Samuel, Shimon Slavin	19
9	Should Soybean Agglutinin Purging Be Performed in Breast Cancer Patients Undergoing Autologous Stem Cell Transplantation? 1997 ·American Journal of Clinical Oncology ·Rami Ben‐Yosef, Reuven Or, E Naparstek, Joseph Kapelushnik, (unknown), Shimon Slavin, Arnon Nagler	4
10	LOW MOLECULAR WEIGHT HEPARIN FOR THE PREVENTION OF VENO-OCCLUSIVE DISEASE OF THE LIVER IN BONE MARROW TRANSPLANTATION PATIENTS1 1996 ·Transplantation ·Reuven Or, Arnon Nagler, Ofer Shpilberg, Sharon Elad, E Naparstek, Joseph Kapelushnik, (unknown), (unknown), Angela Chetrit, Shimon Slavin, Amiram Eldor	75
11	T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse 1995 ·British Journal of Haematology ·E Naparstek, Reuven Or, Arnon Nagler, Gabriel Cividalli, Dan Engelhard, M Aker, (unknown), Noga Manny, T. Sacks, Zelig Tochner, Lola Weiss, S Samuel, (unknown), G Hale, Herman Waldmann, Seth M. Steinberg, Shimon Slavin	120
12	Successful matched unrelated transplantation from a donor with idiopathic thrombocytopenic purpura (ITP) 1995 ·Medical Oncology ·(unknown), (unknown), Reuven Or, E Naparstek, S Slavin, Arnon Nagler	2
13	Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. 1995 ·PubMed ·Dan Engelhard, H. Elishoov, Reuven Or, E Naparstek, Arnon Nagler, Nurith Strauss, Gabriel Cividalli, Memet Aker, (unknown), A. Simhon	37
14	Autologous bone marrow transplantation for stage IV neuroblastoma: the role of soybean agglutinin purging. 1993 ·PubMed ·Joseph Kapelushnik, Arnon Nagler, (unknown), E Naparstek, Gabriel Cividalli, M Aker, Jayesh Mehta, (unknown), Shimon Slavin	5
15	ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES 1993 ·Experimental Hematology ·E Naparstek, R. Or, Arnon Nagler, Gabriel Cividalli, Dan Engelhard, (unknown), Noga Manny, Lawrence M. Weiss, S Samuel, (unknown), G Hale, Herman Waldmann, Seth M. Steinberg, Shimon Slavin	3
16	Normal hematopoietic reconstitution following ASTA-Z 7557-purged grafts in the absence of in vitro CFU-GM colony growth 1993 ·Leukemia Research ·Arnon Nagler, (unknown), E Naparstek, Reuven Or, (unknown), S Slavin	3
17	Clinical application of intrauterine bone marrow transplantation for treatment of genetic diseases--feasibility studies. 1992 ·PubMed ·S Slavin, E Naparstek, M. Ziegler, Alana A. Lewin	27
18	Cytomegalovirus infection and disease after T cell depleted allogeneic bone marrow transplantation for malignant hematologic diseases. 1989 ·PubMed ·Dan Engelhard, (unknown), Nurith Strauss, Abraham Morag, Memet Aker, E Naparstek, Raphael Breuer, Zohar Ravid, I Sarov, G Lijovetzky	8
19	Long-term culture of human granulocytes and granulocyte progenitor cells. 1986 ·PubMed ·Joel S. Greenberger, Thomas J. FitzGerald, Lisa Rothstein, J.E. Pierce, Mary Ann Sakakeeny, R.R. Weichselbaum, E Naparstek, Peter E. Newburger, J D Griffin, Robert C. Bast	2
20	PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION 1985 ·Transplantation Proceedings ·Shimon Slavin, Herman Waldmann, Reuven Or, Gabriel Cividalli, E Naparstek, (unknown), Joseph Michaeli, E. Galun, (unknown), S Samuel, Shoshana Morecki, (unknown), (unknown), Z Weshler, G Hale, E. A. Rachmilewitz, Yaīr Reisner	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact